We have performed guided chemoembolization on 84 patients of moderate and advanced carcinoma of liver using adriamycin lipiodol emulsion (A/L) since 1986. Result showed that the rate of improvement of symptoms was 86.1%, in 75% cases the AFP were decreased and in 79.2% the size of tumor were reduced. The mean survival time was 10.3 months which was much higher than that of the control group (5.6 months,Plt;0.001). THe survival rates of 1/2,1,2,3 year were 89.3%,43.4%,13.5% and 3.8% respctively that were significantly higher than those of the control group (51.2%, 11.5%,0) (Plt;0.01). Three patients underwent secondary resection after using A/L chemoembolization ans gelatin spinge central embolization with a longer survival rate. This may be a good method of treatment to the nonresectable liver cancers and may also be an easy way for postoperative observation.
目的 應用聯合微創介入方法治療中晚期肝癌并探討其療效。方法 我院自1998年4月至2008年11月期間采用聯合介入治療的方法，即行經皮股動脈插管肝動脈化療栓塞術，同期行B超引導下經皮穿刺瘤內乙醇注射(PEI)治療中晚期肝癌175例。結果 左肝動脈行肝動脈化療栓塞7例，右肝動脈行125例，單行化療而未栓塞43例； 175例均行B超引導下PEI。隨訪6～28個月，平均19.3個月，死亡15例，其中8例死于肝功能衰竭，7例死于上消化道大出血伴肝癌廣泛轉移。29例存活6～12個月； 146例存活13～28個月，其中27例存活已超過26個月。結論 對于不能切除的中晚期肝癌采用聯合介入治療，因其具有操作簡單、療效可靠、經濟、安全等優點，值得臨床推廣應用。